Related Experiment Video
Updated: Mar 16, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.8K
Particle Beam Re-irradiation in Oligo Recurrent Gynecological Malignancies
A Barcellini1, A Vai2, G Fontana3
1Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|March 14, 2026
Summary
Proton beam radiotherapy (PBRT) and carbon ion radiotherapy (CIRT) show promise as effective and safe salvage treatments for recurrent gynecological cancers. Further research is needed to optimize patient selection and treatment strategies.
Area of Science:
- Oncology
- Radiation Oncology
- Gynecologic Oncology
Background:
- Recurrent gynecological cancers pose a significant clinical challenge.
- Salvage treatment options are limited, necessitating evaluation of advanced radiotherapy techniques.
Purpose of the Study:
- To assess the efficacy and safety of proton beam radiotherapy (PBRT) and carbon ion radiotherapy (CIRT) as salvage therapies.
- To evaluate local control (LC) and objective response rate (ORR) in patients with recurrent gynecological malignancies.
Main Methods:
- Retrospective analysis of 27 patients with recurrent gynecological tumors treated with PBRT or CIRT.
- Primary endpoints: ORR, 1- and 2-year LC rates. Secondary endpoint: toxicity (CTCAE 5.0).
- Kaplan-Meier method for survival analysis; Log-rank test for predictor identification.
Main Results:
- Overall ORR was 68% within 6 months, with no significant difference between PBRT and CIRT.
- 1- and 2-year LC rates were 100% for PBRT versus 83% and 62% for CIRT, respectively (p=0.075).
- Larger lesion volume and lack of ORR correlated with worse LC; lymph node recurrence and lower alpha/beta ratios showed potential association with better LC. Both treatments were well-tolerated with no grade ≥3 toxicities.
Conclusions:
- PBRT and CIRT demonstrate efficacy and safety as salvage treatments for recurrent gynecological cancers in a real-world setting.
- Further validation with larger cohorts and extended follow-up is recommended for patient selection refinement.
